Treatment of patients with late Parkinson’s disease with levodopa/ carbidopa intestinal gel
Keywords:
late PD, social significance, LCIGAbstract
Parkinson’s disease (PD) is a progressive and neurodegenerative disease, which is debilitating for patients, harmful for the personal and social aspects of a patient's life and causes negative psychological effects. The disease is of great social significance. It is estimated that globally, about 6.000.000 people suffer from PD. Taking into consideration that the population of Bulgaria is about 7.500.000, the indicative number of sick people must be about 12.000-13.000. This number increases linearly each year due to aging of the population, better admission to specialists and better information about the disease. About 1200-1300 people in Bulgaria must be in the late stages of PD. In the late stages of PD, medications are less effective than in the earlier stages of the disease, there are numerous side effects, which restrict their effective use. To help of patients and their relatives, there is one innovative, but approved method of treatment for late PD with levodopa/cardbidopa intestinal gel (LCIG).
References
Petrova, T., Milanov I., Semerdzhieva, N., Duodenal levodopa infusion for the treatment of advanced Parkinson's disease. J Clin Med. 2011; 4.1, 60-65.
Semerdzhieva, N., Milanov, I., Treatment of advanced Parkinson's disease with Duodopa. J Clin Med. 2010; 3 (1): 43-48
Kurlan R, Rubin AJ, Miller C, Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. 1986 Aug;20(2):262-5.
Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci. 2008 Dec;29 Suppl 5:S387-8.
Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S120-2.
Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa. Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal. 2013;15(2):316-323.
Olanow CW, Kieburtz K, Odin P, et al. Double-Blind, Double-Dummy, Randomized Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease. The Lancet Neurology. 2014;13(2):141-149.
Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(Suppl):S13–S17
Nyholm D. Duodopa treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012;18(8):916–929.
Patel PH, Willis M, Thomas E. Percutaneous endoscopic gastrostomy tube deterioration: how common is the problem? Am J GastroenteroI1987;82:806.
Santos-García, D., Sanjurjo, L. F., Macías, M., Llaneza, M., Carpintero, P. and de la Fuente-Fernández, R. Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurologica Scandinavica, 2012; 125: 187–191
Olanow, C. W. and Schapira, A. H. V. Therapeutic prospects for Parkinson disease. Ann Neurol., 2013; 74: 337–347
Antonini A, Yegin A, Preda C, Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015 Mar; 21(3): 231-5.
Slevin JT, Fernandez HH, Zadikoff C, Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis. 2015;5(1):165-74.
Zibetti, M., Merola, A., Artusi, C. A., Rizzi, L., Angrisano, S., Reggio, D., De Angelis, C., Rizzone, M. and Lopiano, L. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol, 2014; 21: 312–318.
Nyholm D, Nilsson Remahl AI, Dizdar N, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005 Jan 25;64(2):216-23.
Devos, D., the French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease . Mov. Disord., 2009; 24: 993–1000.
Zibetti, M., Merola, A., Ricchi, V. et al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol (2013) 260: 105.
Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol. 2010 Oct; 20 (10):683-7.
Toth, C., Breithaupt, K., Ge, S., Duan, Y., Terris, J. M., Thiessen, A., Wiebe, S., Zochodne, D. W. and Suchowersky, O. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol., 2010; 68: 28–36.
Müller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother. 2008 Jun;8(6):957-67.
Santos-García, D., Añón, M. J., Fuster-Sanjurjo, L. and de la Fuente-Fernández, R. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. European Journal of Neurology, 2012; 19: 1261–1265.
Antonini A. Continuous dopaminergic stimulation--from theory to clinical practice. Parkinsonism Relat Disord. 2007 Sep;13 Suppl:S24-8.
Lopiano L, Modugno N, Marano P, et al. Motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. Neurological Sciences. 2016;37(11):1785-1792.
Puente V, De Fabregues O, Oliveras C, Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2010 Mar;16(3):218-21
Foltynie, T. Magee, C. James, C. “Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series,” Parkinson’s Disease, vol. 2013, Article ID 362908, 5 pages, 2013.
Deuschl G, Schade-Brittinger C, Krack P, A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006 Aug 31;355(9):896-908.
Olanow, C. W., Lees, A. and Obeso, J. Levodopa therapy for Parkinson's disease: Challenges and future prospects. Mov. Disord., 2008; 23: S495–S496
Antonini A, Tolosa E, Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother , 2009, 9:859–867
Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L. Assessment of efficacy and safety in duodenal levodopa infusion in advanced Parkinson’s disease. Rev Neurol 2009 Jan 14
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Elena Chorbadjieva, I. Milanov
This work is licensed under a Creative Commons Attribution 4.0 International License.
